Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Tetrazoles (including hydrogenated)

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514183000 - Heterocyclic carbon compounds containing a hetero ring having chalcogen (i.e., O,S,Se or Te) or nitrogen as the only ring hetero atoms DOAI

514359000 - Five-membered hetero ring containing at least one nitrogen ring atom (e.g., 1,2,3-triazoles, etc.)

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
514382000 Additional chalcogen containing hetero ring 25
Entries
DocumentTitleDate
20080269305Dual-acting antihypertensive agents - The invention is directed to compounds having the formula:10-30-2008
20090215843Tetrazole Derivatives and Their Use for the Treatment of Cardiovascular Diseases - The present application relates to novel tetrazole derivatives, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for producing medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prevention of cardiovascular disorders.08-27-2009
20090170917Acid Mimic Compounds for the Inhibition of Isoprenyl-S-Cysteinyl Methyltransferase - Among other things, the present invention provides novel compounds capable of effectively inhibiting inflammatory responses that are mediated by G-proteins or GPCRs in neutrophils, macrophages and platelets. In particular, compounds of the present invention act as inhibitors of edema, inhibitors of erythema and inhibitors of MPO (myeloperoxidase), pharmaceutical compositions containing the same compounds and the use thereof for the treatment of diseases that may benefit from edema, erythema and MPO inhibition, such as inflammation (acute or chronic), asthma, autoimmune diseases, and chronic obstructive pulmonary disease (COPD) (e.g., emphysema, chronic bronchitis and small airways disease, etc.), inflammatory responses of the immune system, skin diseases (e.g., reducing acute skin irritation for patients suffering from rosacea, atopic dermatitis, seborrheic dermatitis, psoriasis), irritable bowel syndrome (e.g., Chron's disease and ulcerative colitis, etc.), and central nervous system disorders (e.g., Parkinson's disease).07-02-2009
20130158087TG2 INHIBITORS AND USES THEREOF - Methods and compounds for treating cancer, dmg resistance and/or metastasis are described herein. These methods and compounds can inhibit the expression of aberrant TG2 expression and/or inhibit the binding of GTP to TG2, and thereby prevent the induction of epithelial to mesenchymal transition of cancer cells, and a stem cell-like phenotype.06-20-2013
20130158086METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITION - The invention relates a pharmaceutical composition comprising a combination of: 06-20-2013
20130158085METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITION - The invention relates a pharmaceutical composition comprising a combination of: 06-20-2013
20130158084Pharmaceutical Composition Comprising Losartin For Treating or Preventing Statin BasedGrug-Induced Muscle Toxicity - A pharmaceutical composition comprising losartan or a pharmaceutically acceptable salt thereof, which is capable of treating or preventing side effects such as muscle toxicity caused by administering a statin-based lipid-lowering drug, and a pharmaceutical combination composition comprising a statin drug and a losartan drug as active ingredients are provided. The pharmaceutical composition comprising losartan or a pharmaceutically acceptable salt thereof provides an effect on treating or preventing muscle-related side effects caused by administration of a statin drug for treating hyperlipidemia, as well as an intrinsic pharmacological effect for treating or preventing hypertension. When administered along with a statin drug in sequence or co-administered at the same time with the statin drug, the pharmaceutical composition can exhibit an effect of effectively or significantly decreasing or preventing side effects such as muscle toxicity.06-20-2013
20130041001VALSARTAN DERIVATIVES CARRYING NITROGEN OXIDE DONORS FOR THE TREATMENT OF VASCULAR AND METABOLIC DISEASES - Nitrate esters and diazeniumdiolate derivatives of valsartanamide are described. They have valuable properties in the treatment of vascular and metabolic diseases.02-14-2013
20090124677Method For Obtaining A Pharmaceutically Active Compound (Irbesartan) And Its Synthesis Intermediate - It is provided a method for obtaining Irbesartan polymorph A, with few synthesis steps, by coupling the intermediate of formula (II) with the compound of formula (III), neutralising one of its alkaline salts in an aqueous medium and recrystallising the crude product obtained. The utilisation of said method obviates protection and deprotection of the tetrazole ring and is therefore of considerable interest for obtaining Irbesartan on a large industrial scale. The invention also refers to the synthesis intermediate of formula (II).05-14-2009
20090326025NEW PHARMACEUTICAL COMPOSITION - The invention provides a new pharmaceutical compositions for treating cardiovascular disease, which contains the active component 2-butyl-4-chloro-1-[2′-(1H-tetrazol-5-yl)1,1′-biphenyl-methyl]imidazole-5-carboxylic acid, 1-[(isopropoxy)carbonyloxy]methyl ester dispersing in pharmaceutically acceptable carriers. The composition can be prepared to solid dosage forms e.g. powders, granules, dripping pills, micro-pellets, tablets, capsules, lozenges etc. by mouth or other way e.g. sublingual administration etc.12-31-2009
20090306159Inhibition of Intermediate-Conductance Calcium Activated Potassium Channels in the Treatment and/or Prevention of Atherosclerosis - Methods for treating or preventing atherosclerosis in human or non-human animal subjects by inhibiting or blocking intermediate-conductance calcium activated potassium channels associated with vascular smooth muscle and/or other cells which play a role in the pathogenesis of atherosclerosis (e.g., KCa3.1, KCNN4, IKCa1, IK1, SK4 channels).12-10-2009
20130059897RAPID RELEASE IRBESARTAN-CONTAINING PHARMACEUTICAL COMPOSITION - The present invention relates to an irbesartan-containing pharmaceutical composition, in particular a tablet thereof, which comprises the active ingredient, a disintegrant with at least one low-substituted hydroxypropyl cellulose.03-07-2013
20110015242PDK-1/AKT SIGNALING INHIBITORS - Use of a new class of phosphoinositide-dependent kinase-1 (PDK-1) inhibitors of formula I for inducing apoptosis in unwanted rapidly proliferating cells, for treating, inhibiting, or delaying the onset of cancer, and for preventing restenosis in a subject that has undergone an angioplasty or stent:01-20-2011
20090270470Compounds I - Compounds of formula I,10-29-2009
20110021585DUAL-ACTING ANTIHYPERTENSIVE AGENTS - The invention relates to compounds having the formula:01-27-2011
20080293790SUBSTITUTED ARYL OXIMES - The present invention relates to substituted aryl oximes and methods of using them.11-27-2008
20080293789VALSARTAN FORMULATIONS - The present invention relates to a new pharmaceutical formulation in the form of a tablet consisting of valsartan as an active agent, pregelatinized starch, microcrystalline cellulose.11-27-2008
20080293788Methods and Compositions for the Treatment of Pulmonary Diseases - This invention related to methods of treating, preventing and managing various pulmonary diseases or disorders using formoterol in combination with calcium activated potassium channel openers. Pharmaceutical compositions comprising formoterol and calcium activated potassium channel openers are also disclosed.11-27-2008
20110028526VALSARTAN SOLID ORAL DOSAGE FORMS AND METHODS OF MAKING SUCH FORMULATIONS - The invention relates to melt granulation processes for preparing immediate release and sustained release pharmaceutical formulations comprising valsartan.02-03-2011
20090048316Pharmaceutical composition comprising candesartan cilexetil - The present invention encompasses pharmaceutical compositions comprising candesartan cilexetil, an amino acid and a pharmaceutically acceptable excipient, and processes for preparing the same.02-19-2009
20100267785CANDESARTAN CILEXETIL - Candesartan cilexetil-containing granules which include a sugar alcohol and a binder and which are produced by granulation with an alcoholic granulating liquid. The granules are suitable for producing tablets in which the candesartan cilexetil is present in a form stabilized with regard to decomposition.10-21-2010
20090149521DUAL-ACTING BENZOIMIDAZOLE ANTIHYPERTENSIVE AGENTS - The invention relates to compounds having the formula:06-11-2009
200900429601-Cycloalkyl-5-Iodotetrazoles - The compounds of the formula (I)02-12-2009
20090137648PROCESS FOR THE PREPARATION OF IRBESARTAN HYDROCHLORIDE - The present invention is concerned with a process for the preparation of 2n-butyl-4-spirocyclopentane-1-[(2′-(tetrazol-5-yl)biphenyl-4-yl)methyl]-2-imidazolin-5-one hydrochloride, irbesartan hydrochloride, novel hydrated and anhydrous crystalline forms thereof, amorphous irbesartan hydrochloride, formulations containing the same, therapeutic uses thereof and methods of treatment employing the same. The process of the present invention is a one-pot process which comprises reacting intermediate compounds 2n-butyl-1,3-diazaspiro[4,4]non-1-en-4-one and 5-(4′-bromomethyl-biphenyl-2-yl)-1-trityl-1H-tetrazole.05-28-2009
20090105322PHARMACEUTICAL COMPOSITION COMPRISING VALSARTAN - The invention relates to pharmaceutical compositions and a method of preventing or reducing the incidence of AF and thereby reducing the risk of morbidity and mortality in patients having symptomatic heart failure comprising administering to such patient an effective amount of valsartan, or pharmaceutically acceptable salts thereof, alone or in combination with another therapeutic agent, optionally in the presence of a pharmaceutically acceptable carrier.04-23-2009
20090030052PHARMACEUTICAL TABLET COMPOSITIONS CONTAINING IRBESARTAN - A pharmaceutical tablet composition comprising irbesartan and lactose, said composition being essentially free of surfactant.01-29-2009
20090291993Difluorophenol Derivatives and Their Use - The present application relates to novel difluorophenol derivatives, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for producing medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prevention of cardiovascular disorders.11-26-2009
20100035949MICROEMULSION DOSAGE FORMS OF VALSARTAN AND METHODS OF MAKING THE SAME - A drug delivery system, e.g., microemulsion preconcentrate, that spontaneously forms a microemulsion when brought in contact with an aqueous medium. The drug delivery system contains valsartan, a hydrophilic component, a lipophilic component and a surfactant. A particularly useful hydrophilic component in the system is a polymer that is solid at room temperature, e.g., solid PEG.02-11-2010
20090312380NOVEL COMPOSITIONS AND METHODS - This invention relates to active pharmaceutical ingredients (APIs) with specific water surface areas, to pharmaceutical compositions comprising said APIs, to processes for preparing such compositions, and to methods for determining the water surface areas of substances such as APIs and other particles.12-17-2009
20100267788DUAL-ACTING ANTIHYPERTENSIVE AGENTS - The invention is directed to compounds of formula I:10-21-2010
20100120877ADDITIONAL THERAPEUTIC USE - The invention relates to the use of an AT05-13-2010
20090082410CONSTITUTIVELY TRANSLOCATING CELL LINE - The present invention relates to agonist-independent methods of screening for compounds that alter GPCR desensitization. Included in the present invention are cell lines containing GRKs, in which GPCRs are desensitized in the absence of agonist; the GRKs may be modified. The present invention relates to methods to determine if a GPCR is expressed at the plasma membrane, and if the GPCR has an affinity for arrestin. Modified GPCRs which have increased arrestin affinity are included in the present invention. These modified GPCRs are useful in methods to screen for compounds that alter desensitization, including both the agonist-independent methods and agonist-dependent methods described herein.03-26-2009
20100087496NOVEL CINNAMIC AMIDE DERIVATIVES USEFUL AS ION CHANNEL MODULATORS - This invention relates to novel cinnamic amide derivatives that are found to be potent modulators of ion channels and, as such, they are valuable candidates for the treatment of diseases or disorders as diverse as those which are responsive to modulation of ion channels.04-08-2010
20080275096Process for the preparation of valsartan - Provided is a process for preparing valsartan and precursors thereof.11-06-2008
20120071528METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA - The invention is directed to novel compounds of Formula I:03-22-2012
20080207714Diagnosis And Treatment Of Breast Cancer - The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to AGTR1 and LBP markers for breast cancer.08-28-2008
20120295943CYCLOALKYLAMINE DERIVATIVES - Provided is a therapeutic agent for hyperparathyroidism, renal osteodystrophy, hypercalcemia and the like, which has a CaSR activating (agonist) action. A compound represented by the following general formula (1):11-22-2012
20080280964Novel Antibiotics Comprising Bis(1-Aryl-5-Tetrazolyl)Methane Derivatives - The invention relates to the field of antibiotic compositions, both inside and outside the medical field. Presented is a new class of antibiotic compounds, the bis(1-aryl-5-tetrazolyl)methanes, which are especially useful for combating infections with gram-positive bacteria and especially MRSA.11-13-2008
20080306128Preparation of Hydrochloride Salts of Tetrazole Derivative - The present invention relates to sesquihydrate hydrochloride salt of irbesartan and anhydrous hydrochloride salts of irbesartan. Irbesartan used as the starting material for the preparation of the described hydrochlorides of irbesartan can be in any form, e.g. it can be used when contained in a reaction solution, in crude form, in a filtrate containing several solvents, or in anhydrous or any solvated or hydrated form, in amorphous form or any known crystal form or in a mixture thereof.12-11-2008
20080293791VALSARTAN SALTS - The invention relates to new salts of valsartan or crystalline, also partly crystalline and amorphous salts of valsartan, the respective production and usage, and pharmaceutical preparations containing such a salt.11-27-2008
20080200527Cannabinoid Receptor Modulators - Compounds of formula (I), are cannabinoid CB1 receptors, useful, inter alia in the treatment of obesity:08-21-2008
20100137387BETA-KETO-AMIDE DERIVATIVES USEFUL AS ION CHANNEL MODULATORS - This invention relates to novel β-keto-amide derivatives that are found to be potent modulators of ion channels, and in particular potassium channels and chloride channels, and, as such, are valuable candidates for the treatment of diseases or disorders as diverse as those which are responsive to the modulation of potassium channels.06-03-2010
20120196908BENZYL ARALKYL ETHER COMPOUNDS, METHOD FOR PREPARING SAME, INTERMEDIATE COMPOUNDS, USE OF SAID COMPOUNDS, METHOD FOR TREATMENT AND/OR PREVENTION, PHARMACEUTICAL COMPOSITION AND MEDICAMENT CONTAINING SAME - This invention describes new antifungal compounds that are aralkyl benzyl ethers of the formula (I):08-02-2012
20090042961OXIME DERIVATIVE SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS - The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.02-12-2009
20090054506Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use - Substituted aryl and heteroaryl derivatives are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.02-26-2009
20100004302Methods for Treating Degenerative Diseases/Injuries - Invented is a method of treating degenerative diseases/injuries, in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist to such mammal.01-07-2010
20090326024SALTS OF IMIDAZOLE-5-CARBOXYLIC ACID DERIVATIVES, A METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME - The present invention provides pharmaceutically acceptable salts of imidazole-5-carboxylic acid derivatives, methods for preparing same and pharmaceutical compositions comprising same. The salts obtained by the present invention can be easily dissolved in common solvents, such as water and methanol. The bioavailability thereof is good in animal body. Thereby it is applicable to be developed as a normal preparation for treating hypertension.12-31-2009
20110230532NITROOXY CYCLOALKANE DERIVATIVES - A compound having the structure wherein Y is selected from the group consisting of —C(O)OR09-22-2011
20090105321Indole Amide Derivatives as Ep4 Receptot Ligands - The invention is directed to indoline amide derivatives as EP4 receptor ligands, antagonists or agonists, useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis, cancer and glaucoma. Pharmaceutical compositions and methods of use are also included.04-23-2009
20080262059METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITION - The invention relates a pharmaceutical composition comprising a combination of: 10-23-2008
20080262058Macrocylic Inhibitors of Hepatitis C Virus - Inhibitors of HCV replication of formula (I)10-23-2008
20090247595Process for the preparation of tetrazolyl compounds - The invention provides a method for preparing candesartan cilexetil and related tetrazolyl compounds. More particularly, the invention relates to the preparation of candesartan cilexetil and related tetrazolyl compounds and includes a method of removing a protective group (e.g., triphenylmethane (trityl) protecting group) from an N-protected tetrazolyl compound using a Lewis acid in an inert solvent and in the presence of an alcohol (e.g., reacting an N-protected tetrazolyl compound with ZnCl10-01-2009
20090258918EP4 receptor agonist, compositions and methods thereof - This invention relates to potent selective agonists of the EP10-15-2009
20090048317Formulations of candesartan - The present invention encompasses pharmaceutical compositions comprising candesartan and processes for preparing the same. In particular, a pharmaceutical composition comprising candesartan or a prodrug thereof or an analog thereof or a derivative thereof and at least one non-ionic surfactant, wherein the pharmaceutical composition has about 0.01% to about 10% of at least one non-ionic surfactant present in the total weight of the composition.02-19-2009
20100184814Ester Derivatives of Losartan, Methods for Their Preparation, and Uses Thereof - The present invention relates to compounds represented by the formula (I) as prodrugs of the formula (II) (Losartan) and their salts, solvates, hydrates, polymorphs, optical isomers, enantiomers, and pharmaceutical compositions comprising these compounds and methods of preparing them and administering them for the treatment of circulatory diseases such as hypertension, congestive heart failure, angina, and the like.07-22-2010
20090298899EP2 RECEPTOR AGONISTS - The disclosure provides EP12-03-2009
20100152258ANGIOTENSIN II RECEPTOR ANTAGONISTS - A compound having the structure (Formula I), wherein Y is —Y06-17-2010
20100152259ANGIOTENSIN II RECEPTOR ANTAGONISTS - A compound having the structure (Formula I), wherein R an angiotensin receptor antagonist active group, Y is Y06-17-2010
20090076104DEUTERIUM-ENRICHED LOSARTAN - The present application describes deuterium-enriched losartan, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.03-19-2009
20100144811COMBINATION - The present invention relates to a combination, especially a pharmaceutical composition, comprising as active ingredients 06-10-2010
20100144810ANGIOTENSIN II RECEPTOR ANTAGONISTS - A compound having the structure06-10-2010
20100144809NOVEL BENZAMIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS - This invention relates to novel benzamidine derivatives of formula (I) that are found to be potent modulators of potassium channels and, as such, are valuable candidates for the treatment of diseases or disorders as diverse as those which are responsive to the modulation of potassium channels. A stereoisomer or a mixture of its stereoisomers, or an N-oxide thereof, or a pharmaceutically-acceptable addition salt thereof, wherein B may be absent (i.e. no heterocyclic ring is formed); and when absent, the nitrogen next to B holds a hydrogen (i.e. “NH”), and A represents NH06-10-2010
20130190370Novel Tetrahydronaphalene Antagonists to the Thromboxane A2 (TP) Receptor - The present invention relates to TP receptor antagonists, which have the ability to bind to TP receptor and optionally cross the blood brain barrier. The invention also provides compositions and methods for treating a disorder wherein activation of TP receptor is detrimental.07-25-2013
20100267789TABLET FORMULATIONS COMPRISING VALSARTAN - The invention relates to solid oral dosage forms comprising pharmacologically effective amounts of valsartan or a pharmaceutically acceptable salt thereof or hydrate thereof. The compositions are at least 1.2 times more bioavailable than conventional valsartan capsule.10-21-2010
20090318518INDOLE AND INDOLINE CYCLOPROPYL AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS - The invention is directed to indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis and cancer. Pharmaceutical compositions and methods of use are also included.12-24-2009
20090318517Novel Compounds 148 - This invention relates to novel pharmaceutically useful compounds of formula (I), in particular compounds that are competitive inhibitors of trypsin-like serine proteases, especially thrombin, their use as medicaments, pharmaceutical compositions containing them and synthetic routes to their production.12-24-2009
20090111861Phthalamide Derivative, Agricultural or Horticultural Pesticide, and Use of the Pesticide - Disclosed is a phthalamide derivative represented by the general formula (I) or a salt thereof, which shows an excellent controlling effect for use as an agricultural or horticultural insecticide alone or in combination with other agricultural or horticultural insecticide, acaricide, nematicide, fungicide, herbicide, plant growth regulator, biopesticide or the like.04-30-2009
200900365065-Iodotetrazoles - The compounds of the formula (I)02-05-2009
20110009463GERANYLGERANYL TRANSFERASE INHIBITORS AND METHODS OF MAKING AND USING THE SAME - The present invention is directed to compounds useful in the treatment of diseases associated with prenylation of proteins and pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising same, and to methods for inhibiting protein prenylation in an organism using the same.01-13-2011
20090048318METHODS FOR TREATING DEGENERATIVE DISEASES/INJURIES - Invented is a method of treating cardiovascular disease/injury, in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist to such mammal.02-19-2009
20100152260CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES - The present invention provides novel pyrazoles that are useful as cannabinoid receptor antagonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, and/or cardiometabolic disorders.06-17-2010
20100048654USE OF VALSARTAN OR ITS METABOLITE TO IN HIBIT PLATELET AGGREGATION - The invention relates to a method of inhibiting platelet aggregation comprising administering a therapeutically effective amount of an ARB or its metabolite, especially Valsartan or its metabolite valeryl 4-hydroxy valsartan. Conditions to be treated by inhibition of platelet aggregation include acute myocardial infarction, ischemic stroke, angina pectoris, acute coronary syndromes, TIA (transient ischemic attacks, or acute cerebrovascular syndromes), heart failure, chest pain of ischemic etiology, syndrome X, thromboembolism, pulmonary hypertension, diabetes mellitus, peripheral vascular disease, deep vein thrombosis, arterial thrombosis of any vessel, catheter thrombotic occlusion or reocclusion.02-25-2010
20090215844Compositions Comprising Nebivolol - Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such hypertension, congestive heart failure, arterial stiffness and endothelial dysfunction. The present invention features a pharmaceutical composition comprising nebivolol and at least one other active agent, wherein the at least one other active agent is a cardiovascular agent.08-27-2009
20110251248GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS - Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.10-13-2011
20110213004METHOD OF USING COMBINATION PREPARATION COMPRISING ANGIOTENSIN-II-RECEPTOR BLOCKER AND HMG-COA REDUCTASE INHIBITOR - Disclosed herein is a combination therapy and a combination preparation of an angiotensin-II-receptor blocker and an HMG-CoA reductase inhibitor characterized in that the angiotensin-II-receptor blocker is absorbed substantially later than the HMG-CoA reductase inhibitor. As the angiotensin-II-receptor blocker and the HMG-CoA reductase inhibitor are released at different times, the present combination therapy prevents competitive inhibition between the two drugs and side effects, as well as simultaneously provides synergistic effects for each active ingredient and convenience of taking the drugs.09-01-2011
20080214638Anthranilic Acid Derivatives Active as the Hm74a Receptor - Therapeutically active anthranilic acid derivatives of Formula (I) or of Formula (Ia) wherein R, R09-04-2008
20100179203NOVEL PYRAZOLE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS - This invention relates to novel pyrazole derivatives that are found to be potent modulators of potassium channels and, as such, are valuable candidates for the treatment of diseases or disorders as diverse as those which are responsive to the modulation of potassium channels.07-15-2010
20090176848FORTIFIER - An agent for enhancing therapeutic or prophylactic effect of a renin-angiotensin system inhibitor on renal diseases is disclosed, including a specific prostaglandin I derivative such as beraprost sodium as an effective ingredient.07-09-2009
20100029734METHODS FOR BREAST CANCER SCREENING AND TREATMENT - A method for selecting a breast cancer patient for therapy with an agent that reduces production of angiotensin II, for example an ACE inhibitor or renin inhibitor, comprises (a) determining whether the cancer comprises a tumor that is estrogen receptor positive (ER+) and (b) selecting the patient for such therapy only if the cancer is determined to comprise an ER+ tumor. A method for treating breast cancer in a patient further comprises (c) administering to the patient, if so selected, an agent that reduces production of angiotensin II, for example an ACE inhibitor or renin inhibitor. A method for treating a breast tumor in a patient having SERM-resistant ER+ breast cancer comprises administering to the patient an agent that reduces production of angiotensin II, for example an ACE inhibitor or renin inhibitor. A therapeutic combination useful in treatment of a breast tumor comprises an agent that reduces production of angiotensin II, for example an ACE inhibitor or renin inhibitor, and a second agent that comprises (a) an aromatase inhibitor or (b) an estrogen receptor modulator or antagonist.02-04-2010
20100267786DUAL ACTING PHARMACEUTICAL COMPOSITIONS BASED ON SUPERSTRUCTURES OF ANGIOTENSIN RECEPTOR ANTAGONIST/BLOCKER (ARB) AND NE UTRAL ENDOPEPTIDASE (EP) INHIBITOR - Solid oral dosage forms, especially tablets, of a pharmaceutical composition comprising a supramolecular complex can be formed from a direct compression process or a compaction process such as roller compaction. Such solid oral dosage forms feature an immediate release profile that allows for fast release of the therapeutic agent. A particularly useful supramolecular complex is trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(S)-3′-methyl-2′-(pentanoyl{2″-(tetrazol-5-ylate)biphenyl-4′-ylmethyl}amino)butyrate]hemipentahydrate.10-21-2010
20100168193THERAPEUTIC USE OF IMIDAZOLE-5-CARBOXYLIC ACID DERIVATIVES - The invention discloses the use of 2-butyl-4-chloro-1-[2′-(1H-tetrazol-5-yl)1,1′-biphenyl-methyl]-imidazole-5-carboxylic acid, 1-[(isopropoxycarbonyl)oxy] methyl ester and the pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment of the damage of a target organ caused by hypertension. It particularly discloses the use of this compound in the manufacture of a medicament for the treatment of left ventricular hypertrophy, renal dysfunction, aorta thickening caused by hypertension, which provides an effective drug and method for the treatment of the damage of target organs for hypertension patients.07-01-2010
20100204292Pharmaceutical compositions comprising intra-and extra-granular fractions - A pharmaceutical composition comprising i) an intra-granular fraction containing a pharmaceutically acceptable active component and a first excipient and ii) an extra-granular fraction containing a second excipient. The pharmaceutical composition is characterized by being substantially surfactant-free and by exhibiting a rapid-dissolution profile.08-12-2010
20090036505Imidazole-5-Carboxylic Acid Derivatives, The Preparation Method Therefor and The Uses Thereof - The invention discloses imidazole-5-carboxylic acid derivatives, and their preparation methods. The derivatives of the invention are Angiotensin II receptor antagonists with angiotensin II antagonistic activity and antihypertensive activity, and thereby can be used as a therapeutical agent to treat hypertension.02-05-2009
201002168541,3 AND 1,3,5 SUBSTITUTED IMIDAZOLES AS ANTIHYPERTENSIVES - The present invention provides novel 1,5 and 1,3,5-substituted imidazole compounds of formulas (I), (IIa), (IIIb) in hydrophilic or lipophilic form, which are useful as angiotensin II AT1 receptor antagonists with sympathetic suppressant properties. In particular, the invention provides pharmaceutical compositions containing the pharmacophoric groups of Losartan and Clonidine as well compounds, processes and intermediates for preparing compounds and their use in methods of treating hypertension and cardiovascular diseases through Renin Angiotensin System (RAS) and Sympathetic System (SS). Alkylated histamine based double action Saltans are lipophilic and can act transdermally.08-26-2010
20080214637Process for the Synthesis of Tetrazoles - A process for the synthesis of tetrazol derivative has been developed which starts from a tetrazole derivative where acidic hydrogen atom has been replaced by a protecting group and the deprotection is performed with a catalytic amount of organic acid and can proceed in an aqueous solvent.09-04-2008
20120115917COMBINATION THERAPY FOR THE MANAGEMENT OF HYPERTENSION - The present invention includes a combination comprising: a) mecamylamine; and b) an ACE inhibitor, an AT2 receptor inhibitor, a renin inhibitor, or a combination thereof.05-10-2012
20120010258ADDITIONAL THERAPEUTIC USE - The invention relates to the use of an AT01-12-2012
20090156655GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES - The present invention discloses novel compounds of Formula (I), or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.06-18-2009
20110086896Crystalline and Stable Form of Andolast - Described is a new crystalline Form A of Andolast disodium salt, triclinic, displaying a thermal event at 98-112° C. and melting with decomposition at about 400° C. (DSC). Andolast disodium Form A is a not hygroscopic solid, surprisingly stable to several humidity conditions in a temperature range acceptable for ordinary storage conditions. In addition its stability allows both chemical manufacturing and pharmaceutical manufacturing process consistency and reproducibility under conditions more viable and less expensive when compared to those used for highly hygroscopic solids.04-14-2011
20120309800METALLOENZYME INHIBITOR COMPOUNDS - The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.12-06-2012
20110105574PAI-1 EXPRESSION AND ACTIVITY INHIBITORS FOR THE TREATMENT OF OCULAR DISORDERS - The invention concerns in one embodiment a method for treating glaucoma or elevated IOP in a patient comprising administering to the patient an effective amount of a composition comprising an agent that inhibits PAI-1 expression or PAI-1 activity. Another embodiment of the present invention is a method of treating a PAI-1-associated ocular disorder in a subject in need, comprising administering to the patient an effective amount of a composition comprising an agent that inhibits PAI-1 activity or expression.05-05-2011
201201229425-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS - The present invention relates to novel pharmaceutically-useful compounds which are antagonists of the 5-oxo-ETE receptors, such as the OXE receptor. These compounds have use as therapeutic and/or prophylactic agents for diseases characterized by tissue eosinophilia, such as inflammatory conditions including respiratory diseases. The invention also relates to pharmaceutical compositions, to the use of such compounds and compositions as medicaments, and to therapeutic methods.05-17-2012
20120122941CYCLOALKYLAMINE DERIVATIVES - Provided is a therapeutic agent for hyperparathyroidism, renal osteodystrophy, hypercalcemia and the like, which has a CaSR activating (agonist) action. A compound represented by the following general formula (1):05-17-2012
20110184035METHODS OF TREATING DEGENERATIVE DISEASES/INJURIES - Invented is a method of treating degenerative diseases/injuries, in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist to such mammal.07-28-2011
20120129900DUAL-ACTING ANTIHYPERTENSIVE AGENTS - The invention is directed to compounds of formula I:05-24-2012
20120252855Methods For Treating Degenerative Diseases/Injuries - Invented is a method of treating cardiovascular disease/injury, in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist to such mammal.10-04-2012
20120178784Use Of Inhibitors Of The Renin-Angiotensin System - It has been found that inhibitors of the rennin-angiotensin system are useful for the treatment or prevention of conditions associated with hypoxia or impaired metabolic function or efficiency. In particular, they may be used in connection with therapy of stroke or its recurrence, the acute treatment of myocardial infarction, and the treatment or prevention of wasting or cachexia, and are thus useful in treatment of the symptoms and signs of aging. These inhibitors may also be used to enhance function in healthy subjects.07-12-2012
20100273845ANGIOTENSIN II RECEPTOR ANTAGONISTS - A compound having the structure10-28-2010
20100010061CB1 RECEPTOR MODULATORS - Compounds of formula (I) suppress the normal signalling activity CB1 receptors, and are thus useful in the treatment of diseases or conditions which are mediated by CB1 receptor signalling activity, such as treatment of obesity and overweight, prevention of weigh gain, treatment of diseases and conditions directly or indirectly associated with obesity and overweight:01-14-2010
20100267787Pharmaceutical Compositions - Provided are compositions comprising aqueous solutions of valsartan suitable for oral administration, preferably in pediatric and geriatric populations. Methods for making such compositions and methods for their stabilization are provided.10-21-2010
20090018175Pharmaceutical excipient complex - The present invention encompasses pharmaceutical excipient complexes comprising combining at least one carrier with an oily substance, and processes for preparing the same, stable pharmaceutical compositions comprising such complexes and active pharmaceutical ingredients and processes for preparing the same.01-15-2009
20120329844VALSARTAN SALTS - The invention relates to new salts of valsartan or crystalline, also partly crystalline and amorphous salts of valsartan, the respective production and usage, and pharmaceutical preparations containing such a salt.12-27-2012
20080242712Identification and uses of novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure - Methods are provided for treating or prophylactically preventing metabolic disorders in humans without causing, promoting, or aggravating fluid retention, peripheral edema, pulmonary edema, or congestive heart failure, by administration of a therapeutically effective amount of a compound sufficient to partially or fully activate peroxisome proliferator activated receptors (PPARs) and partially or fully inhibit, antagonize or block the activity of angiotensin II type 1 receptors. Metabolic disorders that can be treated or prevented include but are not limited to type 2 diabetes, the metabolic syndrome; prediabetes, and other insulin resistance syndromes. Compounds are provided that antagonize or block the angiotensin II type 1 (AT1) receptor, function as partial or full activators of peroxisome proliferator activated receptors (PPARs), can be used to treat or prevent diseases known to be treatable or preventable by PPAR activators and were not previously recognized to be therapeutic targets for angiotensin II receptor antagonists.10-02-2008
20080227836Stable Solid Oral Dosage Forms of Valsartan - A stable solid oral dosage form comprising valsartan or a pharmaceutically acceptable salt thereof and pharmaceutically acceptable additives such as sugar (derivatives) and cellulose (derivatives). The active agent is present in an amount less than 35% by weight based on the total weight of the solid oral dosage form. Disclosed is also a process of forming a valsartan-containing composition; which process comprises blending valsartan with pharmaceutically acceptable additives, dry compressing, milling and screening said mixture to obtain granules. Said granules are compressed into tablets and are subsequently coated.09-18-2008
20080221184Combined agents for treatment of glaucoma - A pharmaceutical composition for the treatment of glaucoma which comprises an angiotensin II antagonist and a prostaglandin which is unoprostone or latanoprost, and a method for treatment of glaucoma by administering the composition to a patient.09-11-2008
20090258919Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and / or congestive heart failure - The present invention relates to use of an inhibitor of the renin-angiotensin system (RAS) or a pharmaceutically acceptable derivative thereof, such as ramipril or ramiprilat, in the prevention of stroke, diabetes and/or congestive heart failure (CHF).10-15-2009
20130137737HIGHLY CRYSTALLINE VALSARTAN - The present invention describes a highly crystalline form of valsartan, pharmaceutical compositions thereof and process for the preparation thereof.05-30-2013
20130137736Methods for Treating Degenerative Diseases/Injuries - Invented is a method of treating degenerative diseases/injuries, in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist to such mammal.05-30-2013
20130123315SUBSTITUTED IMIDAZOLONES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE - The present invention relates to compounds of the general structure shown in Formula (A): (A): and includes pharmaceutically acceptable salts, solvates, esters, prodrugs, tautomers, and isomers of said compounds. Pharmaceutical compositions and methods of treatment are also included.05-16-2013
20080207715Novel Inhibitors of Glutaminyl Cyclase - The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy,08-28-2008
20110224271 PROCESS FOR THE PREPARATION OF OLMESARTAN MEDOXOMIL - The present invention relates to a process for the preparation and purification of trityl olmesartan medoxomil and olmesartan medoxomil.09-15-2011
20100292286Crystalline imidazole-5-carboxylic acid derivative - The invention provides the crystalline imidazole-5-carboxylic acid derivative (I, the chemical name: 2-butyl-4-chloro-1-[2′-(1H-tetrazol-5-yl) 1,1′-biphenyl-methyl]-imidazole-5-carboxylic acid, 1-[(isopropoxy)-carbonyloxy] methyl ester), its preparation method and uses thereof.11-18-2010
20130158088TREATMENT OF HYPERTENSION AND/OR PREVENTION OR TREATMENT OF HEART FAILURE IN A MAMMAL RECEIVING ANTI-COAGULANT THERAPY - The invention relates to methods and pharmaceutical compositions for treating hypertension and/or preventing or treating heart failure in a mammal receiving anti-coagulant therapy using compound(s) which are therapeutically effective but do not impact the pharmacokinetic or the pharmacodynamic effect(s) of the anti-coagulant, such as warfarin.06-20-2013
20130197046NOVEL P2X7R ANTAGONISTS AND THEIR USE - The present application is directed to novel P2X7R antagonists that are indol-3-carboxamide or azaindole-3-carboxamide compounds, pharmaceutical compositions comprising the same and their use for the prophylactic or therapeutic treatment of diseases mediated by P2X7R activity.08-01-2013
20120095067PHARMACEUTICAL COMPOSITION CONTAINING CARBOXYLOSARTAN AND A PRODUCTION METHOD THEREFOR - Disclosed is a pharmaceutical composition containing losartan carboxylic acid and a preparing method thereof. The pharmaceutical composition has the improved dissolution speed and dissolution rate, and the reduced variation in dissolution depending on the pH of a medium.04-19-2012

Patent applications in class Tetrazoles (including hydrogenated)

Patent applications in all subclasses Tetrazoles (including hydrogenated)